Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next year. Trinity Biotech plc

is likely to earn $1.16 per share in the next year ending December, 2015. Trinity Biotech's trailing-twelve-month operating margin is 18.98%. Meridian Bioscience

may earn $1.07 per share in the next year ending September, 2015. Meridian Bioscience's PEG ratio is 2.19. SurModics

is projected to earn $1.01 per share for the next year ending September, 2015. SurModics' trailing-twelve-month revenue is $56.16 million. Neogen

is expected to earn $0.94 per share over the next year ending May, 2015. Neogen's trailing-twelve-month ROE is 10.59%.